Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.72 |
| ▸ | SRC | P12931 | 9/20 | 0.71 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | BCR | P11274 | 2/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379990 | 0.85 | MAP2K1 (0.77) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL4449165 | 0.85 | SRC (0.65) | EGFRERBB2SRCMAP2K1RAF1 | |
| SCHEMBL6381884 | 0.85 | EGFR (0.79) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL4457257 | 0.84 | EGFR (0.69) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL6381737 | 0.84 | EGFR (0.77) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL6380052 | 0.84 | EGFR (1.00) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL6381950 | 0.83 | EGFR (0.72) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL6998642 | 0.83 | EGFR (0.52) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL6379902 | 0.83 | SRC (0.79) | EGFRERBB2SRCMAP2K1ABL1 | |
| SCHEMBL7254131 | 0.83 | SRC (0.69) | EGFRERBB2SRCMAP2K1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | disclosed |
| CN-1165532-C | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | ���Ͽع�����˾ | 2004-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | EGFR 20/4885ERBB2 8/4885SRC 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.